Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC)

Ivan Casaburi, Paola Avena, Arianna De Luca, Adele Chimento, Rosa Sirianni, Rocco Malivindi, Vittoria Rago, Marco Fiorillo, Francesco Domanico, Carmela Campana, Anna Rita Cappello, Federica Sotgia, Michael P. Lisanti, Vincenzo Pezzi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e. IGFII/ IGF1R, ß-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic options and unsuccessful treatments. A useful strategy to develop an effective therapy for ACC is to identify a common downstream target of these multiple pathways. A good candidate could be the transcription factor estrogen-related receptor alpha (ERRa) because of its ability to regulate energy metabolism, mitochondrial biogenesis and signalings related to cancer progression. In this study we tested the effect of ERRa inverse agonist, XCT790, on the proliferation of H295R adrenocortical cancer cell line. Results from in vitro and in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory effect was associated with impaired cell cycle progression which was not followed by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRa was evidenced. Our results indicate that therapeutic strategies targeting key factors such as ERRa that control the activity and signaling of bioenergetics processes in highenergy demanding tumors could represent an innovative/alternative therapy for the treatment of ACC.

Original languageEnglish (US)
Pages (from-to)25135-25148
Number of pages14
JournalOncotarget
Volume6
Issue number28
DOIs
StatePublished - 2015

Fingerprint

Adrenocortical Carcinoma
Estrogen Receptors
Adrenal Cortex Neoplasms
Energy Metabolism
Therapeutics
Catenins
Neoplasms
Investigational Therapies
Autophagy
Organelle Biogenesis
Complementary Therapies
Cell Cycle
Cell Death
Transcription Factors
Pharmacology
Cell Line
Growth

Keywords

  • Adrenocortical cancer
  • ATP depletion
  • ERRa
  • Mitochondria

ASJC Scopus subject areas

  • Oncology

Cite this

Casaburi, I., Avena, P., De Luca, A., Chimento, A., Sirianni, R., Malivindi, R., ... Pezzi, V. (2015). Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget, 6(28), 25135-25148. https://doi.org/10.18632/oncotarget.4722

Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC). / Casaburi, Ivan; Avena, Paola; De Luca, Arianna; Chimento, Adele; Sirianni, Rosa; Malivindi, Rocco; Rago, Vittoria; Fiorillo, Marco; Domanico, Francesco; Campana, Carmela; Cappello, Anna Rita; Sotgia, Federica; Lisanti, Michael P.; Pezzi, Vincenzo.

In: Oncotarget, Vol. 6, No. 28, 2015, p. 25135-25148.

Research output: Contribution to journalArticle

Casaburi, I, Avena, P, De Luca, A, Chimento, A, Sirianni, R, Malivindi, R, Rago, V, Fiorillo, M, Domanico, F, Campana, C, Cappello, AR, Sotgia, F, Lisanti, MP & Pezzi, V 2015, 'Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC)', Oncotarget, vol. 6, no. 28, pp. 25135-25148. https://doi.org/10.18632/oncotarget.4722
Casaburi I, Avena P, De Luca A, Chimento A, Sirianni R, Malivindi R et al. Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget. 2015;6(28):25135-25148. https://doi.org/10.18632/oncotarget.4722
Casaburi, Ivan ; Avena, Paola ; De Luca, Arianna ; Chimento, Adele ; Sirianni, Rosa ; Malivindi, Rocco ; Rago, Vittoria ; Fiorillo, Marco ; Domanico, Francesco ; Campana, Carmela ; Cappello, Anna Rita ; Sotgia, Federica ; Lisanti, Michael P. ; Pezzi, Vincenzo. / Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC). In: Oncotarget. 2015 ; Vol. 6, No. 28. pp. 25135-25148.
@article{7577665b45024fa4b946f66445dd5b62,
title = "Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC)",
abstract = "The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e. IGFII/ IGF1R, {\ss}-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic options and unsuccessful treatments. A useful strategy to develop an effective therapy for ACC is to identify a common downstream target of these multiple pathways. A good candidate could be the transcription factor estrogen-related receptor alpha (ERRa) because of its ability to regulate energy metabolism, mitochondrial biogenesis and signalings related to cancer progression. In this study we tested the effect of ERRa inverse agonist, XCT790, on the proliferation of H295R adrenocortical cancer cell line. Results from in vitro and in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory effect was associated with impaired cell cycle progression which was not followed by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRa was evidenced. Our results indicate that therapeutic strategies targeting key factors such as ERRa that control the activity and signaling of bioenergetics processes in highenergy demanding tumors could represent an innovative/alternative therapy for the treatment of ACC.",
keywords = "Adrenocortical cancer, ATP depletion, ERRa, Mitochondria",
author = "Ivan Casaburi and Paola Avena and {De Luca}, Arianna and Adele Chimento and Rosa Sirianni and Rocco Malivindi and Vittoria Rago and Marco Fiorillo and Francesco Domanico and Carmela Campana and Cappello, {Anna Rita} and Federica Sotgia and Lisanti, {Michael P.} and Vincenzo Pezzi",
year = "2015",
doi = "10.18632/oncotarget.4722",
language = "English (US)",
volume = "6",
pages = "25135--25148",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "28",

}

TY - JOUR

T1 - Estrogen related receptor a (ERRa) a promising target for the therapy of adrenocortical carcinoma (ACC)

AU - Casaburi, Ivan

AU - Avena, Paola

AU - De Luca, Arianna

AU - Chimento, Adele

AU - Sirianni, Rosa

AU - Malivindi, Rocco

AU - Rago, Vittoria

AU - Fiorillo, Marco

AU - Domanico, Francesco

AU - Campana, Carmela

AU - Cappello, Anna Rita

AU - Sotgia, Federica

AU - Lisanti, Michael P.

AU - Pezzi, Vincenzo

PY - 2015

Y1 - 2015

N2 - The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e. IGFII/ IGF1R, ß-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic options and unsuccessful treatments. A useful strategy to develop an effective therapy for ACC is to identify a common downstream target of these multiple pathways. A good candidate could be the transcription factor estrogen-related receptor alpha (ERRa) because of its ability to regulate energy metabolism, mitochondrial biogenesis and signalings related to cancer progression. In this study we tested the effect of ERRa inverse agonist, XCT790, on the proliferation of H295R adrenocortical cancer cell line. Results from in vitro and in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory effect was associated with impaired cell cycle progression which was not followed by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRa was evidenced. Our results indicate that therapeutic strategies targeting key factors such as ERRa that control the activity and signaling of bioenergetics processes in highenergy demanding tumors could represent an innovative/alternative therapy for the treatment of ACC.

AB - The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e. IGFII/ IGF1R, ß-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic options and unsuccessful treatments. A useful strategy to develop an effective therapy for ACC is to identify a common downstream target of these multiple pathways. A good candidate could be the transcription factor estrogen-related receptor alpha (ERRa) because of its ability to regulate energy metabolism, mitochondrial biogenesis and signalings related to cancer progression. In this study we tested the effect of ERRa inverse agonist, XCT790, on the proliferation of H295R adrenocortical cancer cell line. Results from in vitro and in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory effect was associated with impaired cell cycle progression which was not followed by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRa was evidenced. Our results indicate that therapeutic strategies targeting key factors such as ERRa that control the activity and signaling of bioenergetics processes in highenergy demanding tumors could represent an innovative/alternative therapy for the treatment of ACC.

KW - Adrenocortical cancer

KW - ATP depletion

KW - ERRa

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=84944463528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944463528&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4722

DO - 10.18632/oncotarget.4722

M3 - Article

C2 - 26312764

AN - SCOPUS:84944463528

VL - 6

SP - 25135

EP - 25148

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -